Novartis Institutes for BioMedical Research, Horsham, West Sussex, UK.
Expert Opin Ther Pat. 2010 Aug;20(8):987-1005. doi: 10.1517/13543776.2010.495388.
The principle of treating disease with selective adenosine receptor ligands has been demonstrated with drugs on the market, while the lesser understood receptor subtypes are still being probed with new and drug-like pharmaceutical tools. The field of adenosine receptor research is, therefore, highly important as an emerging and proven point of intervention in disease.
From 2008 to 2009, > 120 primary patent applications have claimed adenosine receptor ligands, which we analyze by applicant and target. Particularly significant disclosures are described in detail, paying particular attention to the biological data marshalled to support the case.
The first published disclosure of new compounds, compound uses or drug targets is often in the patent literature, which can be difficult to trawl, interpret and verify as it is not subject to peer review. We have critically reviewed this area and share our conclusions regarding progress, trends and identification of early tool compounds or compounds of potential clinical significance ahead of peer-reviewed publication.
Adenosine receptor research is a thriving field with continuing claims of exciting new compounds with high specificity and intriguing examples of new uses for such ligands.
用市场上的药物证明了用选择性腺苷受体配体治疗疾病的原则，而理解较少的受体亚型仍在使用新的和类似药物的药物工具进行探索。因此，作为疾病干预的新兴和已证实的切入点，腺苷受体研究领域非常重要。
从 2008 年到 2009 年，超过 120 项主要专利申请声称是腺苷受体配体，我们根据申请人和靶标对其进行了分析。特别重要的披露进行了详细描述，特别注意支持该案例的生物数据。
新化合物、化合物用途或药物靶标的首次公开披露通常在专利文献中，这可能很难进行搜索、解释和验证，因为它不受同行评审的限制。我们对这一领域进行了批判性审查，并就进展、趋势以及在同行评审出版物之前识别早期工具化合物或具有潜在临床意义的化合物分享了我们的结论。
腺苷受体研究是一个蓬勃发展的领域，不断有高特异性的令人兴奋的新化合物和此类配体的新用途的令人兴奋的例子被声称。
